Log in

NASDAQ:SCLN - SciClone Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$11.15
0.00 (0.00 %)
(As of 10/20/2017)
Add
Today's Range
$11.15
Now: $11.15
$11.15
50-Day Range N/A
52-Week Range
$8.55
Now: $11.15
$11.43
VolumeN/A
Average Volume444,833 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company's product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company's business is focused primarily in the People's Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Current SymbolNASDAQ:SCLN
CUSIP80862K10
Phone+1-650-3583456

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive SCLN News and Ratings via Email

Sign-up to receive the latest news and ratings for SCLN and its competitors with MarketBeat's FREE daily newsletter.


SciClone Pharmaceuticals (NASDAQ:SCLN) Frequently Asked Questions

What is SciClone Pharmaceuticals' stock symbol?

SciClone Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCLN."

Has SciClone Pharmaceuticals been receiving favorable news coverage?

News stories about SCLN stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. SciClone Pharmaceuticals earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave media stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for SciClone Pharmaceuticals.

Who are some of SciClone Pharmaceuticals' key competitors?

What other stocks do shareholders of SciClone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SciClone Pharmaceuticals investors own include Oncolytics Biotech (ONCYF), Gilead Sciences (GILD), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Skyworks Solutions (SWKS), Rite Aid (RAD), Agenus (AGEN), Array Biopharma (ARRY), Avid Bioservices (CDMO) and Celsion (CLSN).

Who are SciClone Pharmaceuticals' key executives?

SciClone Pharmaceuticals' management team includes the folowing people:
  • Jon S Saxe, Independent Chairman of the Board
  • Friedhelm Blobel Ph.D., President, Chief Executive Officer, Director
  • Wilson W. Cheung, Chief Financial Officer, Senior Vice President - Finance, Secretary
  • Hong Zhao, Chief Executive Officer - China Operations
  • Raymond Anthony Low CPA, Vice President - Finance, Controller
  • Lan Xie CPA, Vice President - Finance, China Chief Financial Officer
  • Nancy T. Chang Ph.D., Independent Director
  • Richard James Hawkins, Independent Director
  • Anthony Gregg Lapointe, Independent Director
  • Simon Li, Independent Director

What is SciClone Pharmaceuticals' stock price today?

One share of SCLN stock can currently be purchased for approximately $11.15.

What is SciClone Pharmaceuticals' official website?

The official website for SciClone Pharmaceuticals is http://www.sciclone.com/.

How can I contact SciClone Pharmaceuticals?

SciClone Pharmaceuticals' mailing address is 950 Tower Ln Ste 900, FOSTER CITY, CA 94404-2125, United States. The specialty pharmaceutical company can be reached via phone at +1-650-3583456.


MarketBeat Community Rating for SciClone Pharmaceuticals (NASDAQ SCLN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  399
MarketBeat's community ratings are surveys of what our community members think about SciClone Pharmaceuticals and other stocks. Vote "Outperform" if you believe SCLN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCLN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/9/2019 by MarketBeat.com Staff

Featured Article: Oversold

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel